Sionna Therapeutics (SION) Equity Ratio (2024 - 2026)

Sionna Therapeutics has disclosed Equity Ratio across 3 years of filings, most recently posting 0.94 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.94, down 0.71% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.94 (down 0.71% YoY), and the FY2025 annual result was 0.94, up 206.81% from the prior year.
• Equity Ratio came in at 0.94 for Q1 2026 at Sionna Therapeutics, roughly flat from 0.94 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.96 in Q2 2025 to a low of 0.88 in Q4 2024.
• The 3-year median for Equity Ratio is 0.95 (2025), against an average of 0.64.
• Across the five-year window, Equity Ratio jumped 206.81% in 2025 and decreased 0.71% in 2026, its largest moves.
• Sionna Therapeutics' Equity Ratio stood at 0.88 in 2024, then surged by 206.81% to 0.94 in 2025, then rose by 0.37% to 0.94 in 2026.
• The last three Equity Ratio figures came in at 0.94 (Q1 2026), 0.94 (Q4 2025), and 0.95 (Q3 2025), per Business Quant data.